MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
MBX Biosciences (Nasdaq: MBX) announced that Kent Hawryluk, President and CEO, will present at the 44th Annual J.P.
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX) announced that Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
Format includes a company presentation and 1x1 meetings at 3:45 p.m. PT / 6:45 p.m. ET in San Francisco. A live webcast will be available via the company’s investor events page, with a replay posted approximately two hours after the events and archived for about 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MBX
On Dec 15, the day this news came out, MBX closed 4.96% below the previous close.
Data tracked by StockTitan Argus for the Dec 15 session.
Key Figures
- Conference dates
- January 12–15, 2026
- J.P. Morgan Healthcare Conference schedule
- Presentation date
- January 13, 2026
- MBX company presentation day
- Presentation time PT
- 3:45 p.m. PT
- Scheduled J.P. Morgan presentation time
- Presentation time ET
- 6:45 p.m. ET
- Scheduled J.P. Morgan presentation time
- Webcast archive period
- approximately 90 days
- Duration replay remains on company website
Historical Context
-
Piper Sandler healthcare conference participation with webcast access for investors.
-
Positive Phase 2 data, cash of $391.7M and funding runway into 2029.
-
Participation in four November investor conferences with webcast access.
-
Stifel virtual cardiometabolic forum fireside chat and webcast.
-
Pricing of upsized public offering of 11.1M shares at $18.00 per share.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco being held on January 12-15, 2026.
44th Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 13, 2026
Format: Company presentation and 1x1 meetings
Time: 3:45 p.m. PT/ 6:45 p.m. ET
Location: San Francisco, California
The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.